状细胞疾病用阿尔金因治疗 (STArT) 的治疗:为第三阶段随机对照试验的研究方案
Chris A Rees1,2, David C Brousseau3, Daniel M Cohen4
1Department of Pediatrics, Division of Pediatric Emergency Medicine, Emory University School of Medicine, 1760 Haygood Drive NE, Atlanta, GA, W45830322, USA.
Trials
|August 16, 2023
概括
该STArT试验调查了静脉注射的阿尔金因是否有效地治疗状细胞疾病 (SCD) 的儿童的疼痛危机. 这项大型研究旨在为SCD血管封闭性发作 (VOE) 这种急需的治疗提供明确的证据.
科学领域:
- 儿科血液学 儿科血液学
- 临床药理学 临床药理学
- 疼痛管理 疼痛管理
背景情况:
- 在患有状细胞疾病 (SCD) 的儿童中,血管封闭性发作 (VOE) 导致严重的疾病负担和医疗保健使用.
- 目前缺乏有效的SCD-VOE疾病修饰疗法.
- 该STArT试验解决了对静脉注射阿基尼因治疗急性SCD-VOE的最终证据的需求.
研究的目的:
- 评估静脉注射阿尔金因在治疗患有状细胞病 (SCD) 的儿童,青少年和年轻成年人急性血管闭塞发作 (VOE) 的疗效.
- 为潜在的SCD-VOE.新疗法提供最终证据.
主要方法:
- 这是一项双盲,安慰剂控制,随机的第三期多中心试验,涉及360名SCD-VOE.患者.
- 参与者接受静脉注射L-阿尔金因或安慰剂,随机化发生在最初的阿片类药物治疗12小时内.
- 主要结局是疼痛危机解决的时间,定义为停止亲口阿片类药物使用.
主要成果:
- 主要结果是SCD-VOE疼痛危机解决的时间.
- 其次性结局包括全体内阿片类药物使用和患者报告的结局.
- 该试验还将分析氨酸代谢组的变化和线粒体功能.
结论:
- 该STArT试验旨在提供关于静脉注射阿尔金因在治疗儿科SCD-VOE.治疗效果的最终信息.
- 杆在紧急医疗和血液学之间建立了参与者积累的网络.
- 旨在为患有状细胞疾病引起疼痛的儿童建立一种新的治疗选择.
更多相关视频
08:23Characterization of Sickling During Controlled Automated Deoxygenation with Oxygen Gradient Ektacytometry
Published on: November 5, 2019
9.9K
05:23Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload
Published on: March 14, 2017
19.5K
相关概念视频
Clinical Trials
6.8K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
6.8K
Phase II Reactions: Sulfation and Conjugation with α-Amino Acids
287
Sulfation and α-amino acid conjugation are two critical biotransformation reactions in drug metabolism. Sulfation, a phase II biotransformation reaction, involves adding a polar sulfate group to a drug, enhancing its water solubility and promoting excretion. This process can either co-occur with or occur independently of glucuronidation. Nonmicrosomal sulfotransferase enzymes catalyze the process. The reaction involves 3'-phosphoadenosine-5'-phosphosulfate or PAPS coenzyme...
287
